title: R5X4 HIV-1 coreceptor use in primary target cells: implications for coreceptor entry blocking strategies.
abstract: Entry coreceptor use by HIV-1 plays a pivotal role in viral transmission, pathogenesis and disease progression. In many HIV-1 infected individuals, there is an expansion in coreceptor use from CCR5 to include CXCR4, which is associated with accelerated disease progression. While targeting HIV-1 envelope interactions with coreceptor during viral entry is an appealing approach to combat the virus, the methods of determining coreceptor use and the changes in coreceptor use that can occur during disease progression are important factors that may complicate the use of therapies targeting this stage of HIV-1 replication. Indicator cells are typically used to determine coreceptor use by HIV-1 in vitro, but the coreceptors used on these cells can differ from those used on primary cell targets. V3 based genetic sequence algorithms are another method used to predict coreceptor use by HIV-1 strains. However, these algorithms were developed to predict coreceptor use in cell lines and not primary cells and, furthermore, are not highly accurate for some classes of viruses. This article focuses on R5X4 HIV-1, the earliest CXCR4-using variants, reviewing the pattern of coreceptor use on primary CD4+ lymphocytes and macrophages, the relationship between primary cell coreceptor use and the two principal approaches to coreceptor analysis (genetic prediction and indicator cell phenotyping), and the implications of primary cell coreceptor use by these strains for treatment with a new class of small molecule antagonists that inhibit CCR5-mediated entry. These are important questions to consider given the development of new CCR5 blocking therapies and the prognosis associated with CXCR4 use.
authors.affiliation: Department of Medicine, University of Pennsylvania School of Medicine, 522 Johnson Pavilion, 36th & Hamilton Walk, Philadelphia, PA 19104-6060, USA.
authors.forename: Lamorris M
authors.initials: LM
authors.lastname: Loftin
authors.forename: Martha
authors.initials: M
authors.lastname: Kienzle
authors.forename: Yanjie
authors.initials: Y
authors.lastname: Yi
authors.forename: Ronald G
authors.initials: RG
authors.lastname: Collman
mesh_terms: D000465:Algorithms; D044966:Anti-Retroviral Agents / Q000627:therapeutic use; D015496:CD4-Positive T-Lymphocytes / Q000821:virology; D003510:Cyclohexanes / Q000627:therapeutic use; D015497:HIV-1 / Q000378:metabolism*; D054298:Human Immunodeficiency Virus Proteins / Q000737:chemistry*; D006801:Humans; D008264:Macrophages / Q000378:metabolism; D000077592:Maraviroc; D010641:Phenotype; D011379:Prognosis; D011485:Protein Binding; D019713:Receptors, CCR5 / Q000737:chemistry*; D019718:Receptors, CXCR4 / Q000737:chemistry*; D014230:Triazoles / Q000627:therapeutic use
chemical_list: D044966:Anti-Retroviral Agents; D003510:Cyclohexanes; D054298:Human Immunodeficiency Virus Proteins; D019713:Receptors, CCR5; D019718:Receptors, CXCR4; D014230:Triazoles; D000077592:Maraviroc